Table 1 Overview of criteria for anatomical response evaluation to immunotherapy
From: PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Criteria (year) [reference] | Categories | |||
|---|---|---|---|---|
Complete response | Partial response | Stable disease | Progressive disease | |
RECIST 1.1 (2009) [20] | • Disappearance of all TL/NTL • Nodal SAD < 1.0 cm • No new lesions | • ≥ 30% decrease of tumour burden relative to baseline • No new lesions | • Neither CR, PR, nor PD | • ≥ 20% increase of tumour burden relative to baseline • Or progression of NTL • Or new lesion(s) |
irRC (2009) [21] | • Disappearance of all lesions (measurable or not) • No new lesions • Confirmation by consecutive CSI control in ≥ 4 weeks | • ≥ 50% decrease of tumour burden relative to baseline • Confirmation by consecutive CSI control in ≥ 4 weeks | • Neither CR, PR, nor PD | • ≥ 25% increase of tumour burden relative to nadir • New lesions added to tumour burden • Confirmation by consecutive CSI control in ≥ 4 weeks |
irRECIST (2013) [22] | • Disappearance of all TL/NTL • Nodal SAD < 1.0 cm • No new lesions | • ≥ 30% decrease of tumour burden relative to baseline • No new lesions | • Neither CR, PR, nor PD | • ≥ 20% increase of tumour burden • And ≥ 5 mm absolute increase in total measured tumour burden relative to nadir (i.e., minimum recorded tumour burden). • Confirmation of progression in ≥ 4 weeks after suspected PD |
iRECIST (2017) [23] | • Disappearance of all TL/NTL • Nodal SAD < 1.0 cm • No new lesions | • Decrease of tumour burden > 30% relative to baseline • No new lesions | • Neither CR, PR, nor PD | iUPD: PD RECIST 1.1 iCPD: • Confirmation 4–8 weeks later • Any further size increase in TL sum > 5 mm • Any progression of NTL • Any further size increase of the sum of new TL > 5 mm • Appearance of another new lesion |